Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Toronto Stock Exchange  >  Cardiome Pharma Corp    COM   CA14159U3010

CARDIOME PHARMA CORP (COM)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Cardiome Pharma Corp
Engages in the discovery, development and commercialization of new therapies

Cardiome Pharma Corp. is a pharmaceutical company, which engages in the provision of development and commercialization of medical products.

It operates through the Europe and Rest of the World geographical segments.

It focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.

It offers the Brinavess and Aggrastat products to customers such as physicians, patients, and healthcare systems.

The company was founded on December 12, 1986 and is headquartered in Vancouver, Canada.

Number of employees : 163 persons.
Sales per Businesses
20162017Delta
CAD (in Million)%CAD (in Million)%
Product and Royalty33.2199.2%30.9199.2% -6.94%
Licensing and Other Fees0.2520.8%0.2560.8% +1.58%
Sales per Regions
20162017Delta
CAD (in Million)%CAD (in Million)%
Rest of World18.9856.7%16.9554.4% -10.72%
Europe14.4843.3%14.2245.6% -1.83%
Managers
NameAgeSinceTitle
William L. Hunter, MD542007President, Chief Executive Officer & Director
William James O'Shea682014Chairman
Sheila M. Grant, MBA-2003Chief Operating Officer
Justin A. Renz MBA, CPA462017Chief Financial Officer
Richard M. Glickman, PhD712006Lead Independent Director
Mark H. N. Corrigan, MD612015Director
Arthur H. Willms782015Independent Director
Robert James Meyer, MD-2015Director
Steen Juul-Möller MD, PhD-2013Medical Director-Europe
Jürgen Polifka, PhD-2013General Manager-European Sales & Marketing
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 34,868,962 33,585,903 96.3% 0 0.0% 96.3%
Shareholders
NameEquities%
Westfield Capital Management Co. LP 4,370,913 13.7%
Putnam Investment Management LLC 3,706,324 11.6%
Stonepine Capital Management LLC 3,158,816 9.91%
Clough Capital Partners LP 2,441,863 7.66%
Tamarack Advisers LP 1,825,000 5.73%
Rock Springs Capital Management LP 1,200,000 3.76%
William L. Hunter, MD 1,020,881 3.20%
Renaissance Technologies LLC 486,613 1.53%
JPMorgan Securities LLC (Investment Management) 161,450 0.51%
David M. Knott Partnership 67,978 0.21%
Company contact information
Cardiome Pharma Corp.
1441 Creekside Drive
6th floor
Vancouver, BC V6J 4S7

Phone : +1.604.677.6905
Fax : +1.604.677.6915
Web : www.cardiome.com
Sector Biopharmaceuticals
1st jan.Capitalization (M$)
CARDIOME PHARMA CORP51.83%79
CSL LIMITED12.91%55 642
BIOGEN-17.71%54 858
ALEXION PHARMACEUTICALS-9.83%23 977
GRIFOLS-4.44%17 583
BIOMARIN PHARMACEUTICAL-7.95%14 452
WUXI BIOLOGICS CAYMAN INC--.--%10 779
CELLTRION HEALTHCARE CO LTD--.--%10 430
CHONGQING ZHIFEI BIOLOGICAL PRDCT CO LTD--.--%9 720
3SBIO INC15.48%5 805
ABCAM PLC20.57%3 673
HUGEL INC--.--%2 252
BOYA BIO-PHARMACEUTICAL GROUP CO LTD--.--%2 147
MYOVANT SCIENCES LTD51.90%1 278
WILSON THERAPEUTICS AB124.69%756
ANIKA THERAPEUTICS INC-16.88%658
CHEMOCENTRYX INC81.18%524
PHARMA MAR SA-31.98%459
VERICEL CORP116.51%439
PROMETIC LIFE SCIENCES INC.-36.92%438
SYROS PHARMACEUTICALS INC24.05%395
Connections : Cardiome Pharma Corp
Michael Smith Foundation for Health Research
Synereca Pharmaceuticals, Inc.
enGene, Inc.
Advanced Applied Physics Solutions, Inc.
Trevi Therapeutics, Inc.
Brighton Biotech, Inc.
MedGenesis Therapeutix, Inc.
The Vancouver Symphony Foundation
Vida Pharmaceuticals Pvt Ltd.
Zalicus Pharmaceuticals Ltd.
Kyowa Kirin International Plc
Pamlico BioPharma, Inc.
Lumira Capital Investment Management, Inc.
Vancouver Symphony Orchestra
Blackthorn Therapeutics, Inc.
British Columbia Lottery Corp.
Richardson Capital Ltd.
The 2010 Games Operating Trust
Premier's Technology Council
Pacific Autism Family Centre Foundation
Kearny Venture Partners
© 2018 People , Fundamentals and Ownership